Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.17
+0.01 (0.12%)
At close: Mar 6, 2026, 4:00 PM EST
8.02
-0.15 (-1.84%)
After-hours: Mar 6, 2026, 6:58 PM EST
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
544.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| CorMedix | 214.30M |
| ADC Therapeutics | 75.21M |
| uniQure | 16.10M |
| Prothena Corporation | 9.68M |
| Allogene Therapeutics | 22.00K |
| Altimmune | 20.00K |
FULC News
- 18 hours ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 9 days ago - Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion - Seeking Alpha
- 10 days ago - Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 11 days ago - Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 18 days ago - Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha